The information in this section is intended for visitors outside the United States.
Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Gilead Grants Intellectual Property Rights for Tenofovir Topical Gel to the International Partnership for Microbicides and CONRAD
Gilead Sciences Receives Subpoena from U.S. Department of Justice
Gilead Sciences to Present at the NASDAQ 18th Investor Program on Thursday, December 7
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences Completes Acquisition of Myogen
Gilead Sciences to Present at the Credit Suisse Healthcare Conference on Friday, November 17th
Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3 Percent of Shares Tendered
Gilead Sciences Completes Acquisition of Raylo Chemicals Inc.
Gilead Sciences Extends Expiration Date for Tender Offer for Myogen Until November 13, 2006
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Gilead Sciences Announces Third Quarter 2006 Financial Results
Gilead Sciences to Release Third Quarter 2006 Financial Results on Wednesday, October 18, 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Landmark Five-Year Data on Gilead's Anti-HIV Drug Viread(R) Presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy
Gilead Announces Licensing Agreements with Eight India-Based Companies for Manufacturing and Distribution of Generic Versions Of Viread in the Developing World
Gilead Sciences to Present at The UBS Global Life Sciences Conference on Monday, September 25th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the Bear Stearns 19th Annual Healthcare Conference on Tuesday, September 12th; Webcast Available Through Gilead Corporate Website
Gilead Sciences' President and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan
Gilead Announces Licensing Agreements with Three India-Based Companies for Manufacturing and Distribution of Generic Versions of Viread in the Developing World
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
Gilead Sciences Completes Acquisition of Corus Pharma
Gilead Sciences and Merck Establish Agreement for Distribution of ATRIPLA(TM) in Developing Countries
Gilead Sciences Exercises Option to Acquire Corus Pharma for $365 Million
Gilead Sciences Announces Second Quarter 2006 Financial Results
Gilead Sciences Agrees to Exercise Its Option to Acquire Corus Pharma for $365 Million
Gilead Sciences to Release Second Quarter 2006 Financial Results on Thursday, July 20, 2006; Conference Call and Webcast to Follow
Gilead Sciences and the Institute of Organic Chemistry and Biochemistry (IOCB) Establish New Academic Research Centre in Prague; Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Gilead Sciences to Present at the William Blair & Company 26th Annual Growth Stock Conference on Wednesday, June 28th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Acquire Degussa's Raylo Chemicals Inc.; Purchase to Expand Gilead's Manufacturing Scale-Up Capacity for Investigational Therapies
Gilead Sciences to Present at the 22nd Annual Sanford Bernstein Strategic Decisions Conference 2006 on Wednesday, May 31st; Webcast Available Through Gilead Corporate Website
Gilead Announces Dismissal of Securities Litigation
Gilead Sciences to Present at the Banc of America 2006 Health Care Conference on Thursday, May 18th; Webcast Available Through Gilead Corporate Website
Gilead Offers Voluntary Licenses for Manufacturing of Viread in Developing World
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
Gilead Closes Sale of $1.3 Billion Convertible Senior Notes
Gilead Prices $1.2 Billion Convertible Senior Notes; Company to Repurchase Approximately $545 Million in Common Stock
Gilead to Offer $1.1 Billion Convertible Senior Notes; Company to Repurchase Approximately $500 Million in Common Stock
Gilead Sciences Announces First Quarter 2006 Financial Results
Gilead Sciences to Release First Quarter 2006 Financial Results on Tuesday, April 18, 2006; Conference Call and Webcast to Follow
Gilead Invests $25 Million in Corus Pharma; Establishes Equity Position in Company With Late-Stage Product Candidate for Cystic Fibrosis
Kristen M. Metza Joins Gilead as Vice President, Human Resources
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R); 48-Week Data from Pivotal Study 934 Added to U.S. Prescribing Information for Both Products
Gilead Sciences to Present at the Citigroup 2006 Healthcare Conference on Tuesday, February 28th; Webcast Available Through Gilead Corporate Website
Gilead Sciences Launches Stop Hep B Campaign; Initiative Aims to Combat Chronic Hepatitis B by Educating and Empowering At-Risk Communities
Gilead Announces Results from Phase I/II Study of Investigational HIV Integrase Inhibitor GS 9137
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Wednesday, February 8th; Webcast Available Through Gilead Corporate Website
Gilead Sciences' Board Member Amends Existing Rule 10b5-1 Stock Trading Plan
Gilead Sciences Announces Fourth Quarter and Full Year 2005 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2005 Financial Results on Monday, January 30, 2006; Conference Call and Webcast to Follow
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial
Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)
Gilead Sciences to Present at the 24th Annual JPMorgan Healthcare Conference on Monday, January 9th; Webcast Available Through Gilead Corporate Website